Answers are grounded in this paper and cite their sources.
The cyclic GMP-AMP synthase (cGAS)-mediated type I interferon (IFN-I) signaling axis plays an essential role in antiviral defense, inflammation, autoimmunity, and cancer. Targeting cGAS represents a promising therapeutic strategy with broad clinical implications. However, currently available small-molecule cGAS agonists remain limited. Here, we identify Fangchinoline (Fan), a natural bibenzyl isoquinoline alkaloid, as a potent cGAS activator. Mechanistically, Fan directly binds and activates cGAS, promoting intracellular cyclic GMP-AMP synthesis and subsequent activation of the STING/TBK1/IRF3 signaling cascade, independent of Toll-like receptor or RIG-I/MDA5 pathways. This activation elicits broad-spectrum antiviral responses via upregulation of interferon-stimulated genes. Importantly, Fan-driven IFN-I signaling remodels the tumor immune microenvironment, enriching cytotoxic CD8 + T lymphocytes and macrophages, thereby exerting potent antitumor effects across multiple murine cancer models and synergizing with anti-PD-1 immunotherapy. Collectively, our results suggest that Fan is a cGAS activator with dual therapeutic efficacy, offering theoretical basis for the treatment of cancer and infectious diseases.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: